These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36086817)

  • 41. InsT-ALLing CD7 chimeric antigen receptors before transplantation.
    Delgado J
    Br J Haematol; 2024 Jun; 204(6):2155-2156. PubMed ID: 38676290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
    Polgárová K; Otáhal P; Šálek C; Pytlík R
    Front Oncol; 2022; 12():876758. PubMed ID: 35600381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
    Xiang J; Devenport JM; Carter AJ; Staser KW; Kim MY; O' Neal J; Ritchey JK; Rettig MP; Gao F; Rettig G; Turk R; Lee BH; Cooper ML; DiPersio JF
    Leukemia; 2023 Dec; 37(12):2448-2456. PubMed ID: 37798328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy.
    Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T
    Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy.
    Kim MY; Cooper ML; Jacobs MT; Ritchey JK; Hollaway J; Fehniger TA; DiPersio JF
    JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
    Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
    J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [CAR T-cell therapy for T cell malignancies: challenges and recent advances].
    Tashiro H
    Rinsho Ketsueki; 2024; 65(7):644-651. PubMed ID: 39098015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management.
    Li S; Wang X; Yuan Z; Liu L; Luo L; Li Y; Wu K; Liu J; Yang C; Li Z; Wang D; Shen L; Ye X; He J; Han C; Wang Y; Zhang D; Dong Y; Fang L; Chen Y; Sersch M; Cao WW; Wang S
    Clin Cancer Res; 2021 Mar; 27(5):1242-1246. PubMed ID: 33234511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
    Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
    Stem Cell Res Ther; 2021 Oct; 12(1):527. PubMed ID: 34620233
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fratricide-resistant CD7-CAR T cells in T-ALL.
    Oh BLZ; Shimasaki N; Coustan-Smith E; Chan E; Poon L; Lee SHR; Yeap F; Tan LK; Chai LYA; Le Bert N; Tan N; Bertoletti A; Chen SP; Del Bufalo F; Becilli M; Locatelli F; Yeoh AEJ; Campana D
    Nat Med; 2024 Dec; 30(12):3687-3696. PubMed ID: 39227445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies.
    Guo Z; Zhang Y; Fu M; Zhao L; Wang Z; Xu Z; Zhu H; Lan X; Shen G; He Y; Lei P
    Front Immunol; 2021; 12():652924. PubMed ID: 33854512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
    Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
    J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells].
    Zhu XY; Liu X; Wang XB; Wang AY; Wang M; Liu NN; You FT; Pan GF; Yang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1367-1375. PubMed ID: 32798428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.